Lucy Coassin

Lucy Coassin is a Principal at Northpond Ventures. She is a board director at Hawthorne Health, Octave Bioscience, SimBioSys, Story Health, and Vital Biosciences, and a board observer at Inflammatix, Faro Health, Triumvira, and Vizgen. Previously, Lucy was Head of Pharma at Current Health (a Northpond portfolio company, acquired by Best Buy).  She has 15 years of experience commercializing technology from product launch to widespread adoption. Lucy has held business development and commercial roles at digital health and life science tool companies including Science 37 (NASDAQ: SNCE), Farcast Biosciences, Genentech, and Life Technologies (Acquired by ThermoFisher, NYSE: TMO). Lucy received her MBA from the Stanford Graduate School of Business and a B.S. with distinction in Chemistry from Duke University.